1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards

 
• By Lucie Ellis-Taitt

Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.

Blood sample
Bluebird looks towards 2017 EU conditional approval for LentiGlobin as beta-thalassemia gene therapy • Source: Shutterstock

Gene therapy specialist bluebird bio Inc. has reported early Phase III data for LentiGlobin (lentiviral beta-globin gene transfer) in patients with transfusion-dependent beta-thalassemia (TDT) that have split analysts' opinions.

Despite mixed figures from the first three patients treated in the Northstar-2 trial, the results have demonstrated that bluebird's improved manufacturing process can address patient-to-patient treatment variability issues.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas